T Cell Immunotherapy an Improvement Over Checkpoint Inhibition
Researchers here report on the results of a phase III trial of tumor infiltrating leukocyte (TIL) therapy for melanoma. A patient's T cells are multiplied outside the body and then injected, along with chemotherapy beforehand to clear existing T cell populations, and IL-2 delivery afterwards to promote replication of the delivered T cells. It has meaningful side-effects, as do other cancer immunotherapies, but the outcome is an improvement over the present standard approach of checkpoint inhibition for melanoma. Even as better approaches to cancer therapy are in development, such as those based on interference in telomere ...
Source: Fight Aging! - December 14, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Barcodes Are Us
BY KIM BELLARD
Usually I write about things where I see some unexpected parallel to healthcare, or something just amazed me, or outraged me (there are lots of things about healthcare like the latter). But sometimes I run across something that just delights me.
So when I inexplicably stumbled across DNA Barcoding Technology for High Throughput Cell-Nanoparticle Study, by Andy Tay, PhD, my first thought was, oh, nanoparticles, that’s always interesting, then it hit me: wait, DNA has barcodes?
How delightful.
We’re all used to barcodes. Pretty much every product in pretty much every store has a b...
Source: The Health Care Blog - November 29, 2022 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: Health Tech Health Technology DNA Barcodes DNA nanotechnology Kim Bellard Source Type: blogs
Making Tumors Tastier for the Immune System
Researchers at The University of Texas MD Anderson Cancer Center have developed a nanotechnology platform that can make cancer cells more vulnerable to immune attack in the body. The researchers call their system the bispecific tumor-transforming nanoconjugate (BiTN) platform.
The idea is to make solid tumors more appealing for the immune system by attaching a molecule that acts as an “eat me” signal to white blood cells. This molecule is called signaling lymphocytic activation molecule family member 7 (SLAMF7) receptor and is more commonly found on cancer cells in blood cancers, which explains the relative success...
Source: Medgadget - November 15, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Medicine Nanomedicine Oncology MDAndersonNews Source Type: blogs
Fight Aging! Newsletter, November 14th 2022
In this study, we show that TXNIP is vital for the cell fate choice when cells are challenged by various stress signals. Furthermore, prolonged IGF1 treatment leads to the establishment of a premature senescence phenotype characterized by a unique senescence network signature. Combined IGF1/TXNIP-induced premature senescence can be associated with a typical secretory inflammatory phenotype that is mediated by STAT3/IL-1A signaling. Finally, these mechanistic insights might help with the understanding of basic aspects of IGF1-related pathologies in the clinical setting.
Investigating the Ability of Type 2 Diabetes...
Source: Fight Aging! - November 13, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Soluble Phosphorylated Tau as a Target in Alzheimer's Disease and other Tauopathies
The primary thrust of Alzheimer's research and clinical development of therapies remains the targeting of amyloid-β and tau aggregates. The failure to produce meaningful benefits in patients, even given reductions in amyloid-β and tau, is not shifting the focus of most research groups to other entirely different approaches, but rather to question whether the complexity of amyloid-β and tau biochemistry means that the wrong locations or types of these molecules were targeted by the immunotherapies used to date in human trials.
For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to b...
Source: Fight Aging! - November 11, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Senescent Cells as a Cancer Vaccine
Researchers here note the discovery that vaccinating mice with senescent cancer cells ensures that the immune system will more aggressively attack a later introduction of cancerous cells. Since we know that most cancer therapies induce senescence in cancerous cells to a fair degree, one has to think that the effectiveness of this approach will diminish as a cancer progresses to form a solid tumor and co-opts the immune system in various ways. Still, it sounds as though it could be a potentially useful after, for example, surgical resection of a tumor, to help reduce the odds that the cancer will reoccur.
Scientis...
Source: Fight Aging! - November 9, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, November 7th 2022
In conclusion, the national prevalence of dementia and MCI in 2016 found in this cross-sectional study was similar to that of other US-based studies.
Clearing Microglia Reverses Age-Related Disruption of Sleeping Patterns in Mice
https://www.fightaging.org/archives/2022/11/clearing-microglia-reverses-age-related-disruption-of-sleeping-patterns-in-mice/
Microglia are innate immune cells of the central nervous system. They are analogous to macrophages in the rest of the body, but undertake additional duties relating to the function of neurons and in brain tissue. Microglia become overly active and inflamm...
Source: Fight Aging! - November 6, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Reprogramming as an Approach to Reduce T Cell Exhaustion
T cell exhaustion occurs following repeated stimulation, such as when faced with a growing cancer or persistent viral infection. It manifests as a progressive loss of function, the T cells no longer attacking pathogens or errant cells. Finding a way to minimize this phenomenon would assist in a range of conditions, such as by improving the outcome of T cell immunotherapies targeting cancer, and might help improve the aged immune system, in which T cell exhaustion is also observed. Here, the use of partial reprogramming is suggested as an approach to achieve this goal. In partial reprogramming, cells are exposed to the fact...
Source: Fight Aging! - October 31, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
3D Bioprinted Breast Tumors for Immunotherapy Testing
A team of scientists at Penn State has bioprinted breast tumor mimics with significant complexity, including a form of vascularization and the ability to precisely place cells in certain locations within the construct. The scientists used a technique called aspiration-assisted bioprinting to achieve this.
With many anti-cancer therapies failing at the clinical trial stage and the ethical considerations of animal studies, there is a need for better in vitro cancer models that allow for advanced therapeutic testing. The models have allowed the researchers to test advanced therapies, including CAR-T immune cell therapies....
Source: Medgadget - October 27, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Materials Medicine Oncology Source Type: blogs
Fight Aging! Newsletter, October 17th 2022
This study investigated whether multimorbidity is associated with incident dementia and whether associations vary by different clusters of disease and genetic risk for dementia. The study used data from the UK Biobank cohort, with baseline data collected between 2006 and 2010 and with up to 15 years of follow-up. Participants included women and men without dementia and aged at least 60 years at baseline. The presence of at least 2 long-term conditions from a preselected list of 42 conditions was used to define multimorbidity.
A total of 206,960 participants (mean age 64.1 years) were included in the final sample, of...
Source: Fight Aging! - October 16, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Cancers Force T Cells into Senescence
We report that both mouse malignant tumor cells and regulatory T cells (Tregs) can induce responder T cell senescence, similar as shown in human Treg and tumor cells. Accumulated senescent T cells also exist in the TME in tumor models of lung cancer, breast cancer, and melanoma. Induction of ataxia-telangiectasia mutated protein (ATM)-associated DNA damage is the cause for T cell senescence induced by both mouse tumor cells and Treg cells, which is also regulated by mitogen-activated protein kinase (MAPK) signaling.
Furthermore, blockages of ATM-associated DNA damage and/or MAPK signaling pathways in T cells can pre...
Source: Fight Aging! - October 13, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
More On Depletion of Soluble Amyloid- β in Alzheimer's Disease
If slow amyloid-β aggregation over years is the cause of Alzheimer's disease, then how to explain the older individuals who have high levels of amyloid-β in the brain, but do not suffer from Alzheimer's disease? Further, how to explain the failure of amyloid-β clearance via immunotherapy in clinical trials? Amyloid-β is successfully cleared from the brain, but patient outcomes do not improve meaningfully. This line of thinking led to the hypothesis, with supporting evidence, that amyloid-β aggregation is pathological only because it depletes levels of soluble amyloid-β. It doesn't cause that issue to the same degree ...
Source: Fight Aging! - October 11, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, October 10th 2022
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - October 9, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
About That Cancer Moonshot
BY KIM BELLARD
Joe Biden hates cancer. He led the Cancer Moonshot in the Obama Administration, and, as President, he reignited it, vowing to cut death rates in half over the next 25 years. Last month, on the 60th anniversary of President Kennedy’s historic call for an actual moonshot, he vowed “to end cancer as we know it. And even cure cancers once and for all.”
But, as several recent studies show, cancer is still surprising us.
—————
Our body has its own defenses against cancer, such as T-cells, and great strides have been made in cancer therapies, including ...
Source: The Health Care Blog - October 6, 2022 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: Health Policy Research Cancer Cancer Progression Fungi John F. Kennedy Moonshot Source Type: blogs
About that Cancer Moonshot
By KIM BELLARD
Joe Biden hates cancer. He led the Cancer Moonshot in the Obama Administration, and, as President, he reignited it, vowing to cut death rates in half over the next 25 years. Last month, on the 60th anniversary of President Kennedy’s historic call for an actual moonshot, he vowed “to end cancer as we know it. And even cure cancers once and for all.”
But, as several recent studies show, cancer is still surprising us.
—————
Our body has its own defenses against cancer, such as T-cells, and great strides have been made in cancer therapies, includi...
Source: The Health Care Blog - October 6, 2022 Category: Consumer Health News Authors: matthew holt Tags: Health Policy Public Health Biden Cancer Cancer Moonshot Source Type: blogs
